Possible Protective Effect of Low Dose of Papaverine on ANIT Induce Cholestasis in Rat

Authors

  • Doaa Adnan Atshan Ministry of Health and Environment, Alnuman Teaching Hospital, Baghdad, Iraq.
  • Munaf H. Zalzala Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq.

DOI:

https://doi.org/10.31351/vol32issSuppl.pp118-126

Keywords:

intrahepatic cholestasis,ANIT,papaverine

Abstract

Abstract

Intrahepatic cholestasis is clinical syndrome which cause either by defect in synthesis or bile acid flow, the pathophysiology of cholestasis is complicated by a number of  variables, including oxidative stress, inflammatory response, and  dysregulation of bile acid transporter . Rats, mice, and guinea pigs were utilized as experimental animals, and ANIT was administered to them in order to create a model that closely resembled intrahepatic cholestasis in human. This study examined the protective effects of papaverine, a non-narcotic opium alkaloid derived from papaver somniferum and discovered as an FXR agonist, on cholestasis in rats induced by alpha-naphthylisothiocyanate (ANIT). Rats utilized in this study divided  into 3 groups (10 rats per each groups), group I (control) or vehicle group  rat administered corn oil (1ml/kg) once daily 48 hour before sacrifice group II rats orally administered alpha-naphthylisothiocyanate (ANIT) 100mg/kg single dose 48hour before sacrifice  group III rats administered 100mg/kg papaverine orally  for 7 consecutive days and  at day 5  rat administered alpha-naphthylisothiocyanate (ANIT) The results showed that papaverine treatment decreased alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, total bile acid, as well as increased antioxidant enzyme GPX and decreased MDA and inflammatory mediators tumor necrosis factor TNF- and interleukin IL1-β. In conclusion, papaverine may have a protective effect to alleviate ANIT-induced cholestasis and may be a therapeutic target to treat cholestasis.

References

Zalzala MH, Kareem VS. The Safranal Effect against Cyclophosphamide-Induced Liver Injury. Iraqi Journal of Pharmaceutical Sciences. 2021 Dec 11;30(2):208-13.

Ahmad HA, Kathem SH. Thymoquinone Attenuates Immune Mediated Liver Injury Induced by Concanavalin A in Mice. Iraqi Journal of Pharmaceutical Sciences. 2021 Dec 9;30(2):50-7.

Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: Modulators and therapeutic targets in liver inflammation. InSeminars in immunopathology 2022 Jul (Vol. 44, No. 4, pp. 547-564). Berlin/Heidelberg: Springer Berlin Heidelberg.

Onofrio FQ, Hirschfield GM. The pathophysiology of cholestasis and its relevance to clinical practice. Clinical liver disease. 2020 Mar;15(3):110.

Chen L, Wei S, Liu H, Li J, Jing M, Tong Y, Li R, Wen J, Zhan H, Zhao Y. Paeoniflorin protects against ANIT-induced cholestatic liver injury in rats via the activation of SIRT1-FXR signaling pathway. Evidence-Based Complementary and Alternative Medicine. 2021 Sep 2;2021.

Sultana H, Komai M, Shirakawa H. The Role of Vitamin K in Cholestatic Liver Disease. Nutrients. 2021 Aug;13(8):2515.

Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Digestive diseases. 2010;28(1):220-4.

van de Wiel SM, Bijsmans IT, van Mil SW, van de Graaf SF. Identification of FDA-approved drugs targeting the Farnesoid X Receptor. Scientific reports. 2019 Feb 18;9(1):1-1

Downloads

Published

2023-11-03